Japanese ophthalmic firm Nitto Medic has entered into an agreement with France-based Nicox for the distribution of diagnostic test AdenoPlus in Japan.

AdenoPlus is an in-vitro diagnostic medical device that aids in the differential diagnosis of acute conjunctivitis.

In June 2012, Nicox in-licensed AdenoPlus from Rapid Pathogen Screening (RPS) and has full exclusive rights to commercialise the device worldwide, except in the US and Canada.

Nicox chairman and chief executive officer Michele Garufi said: "We are delighted to sign this agreement with Nitto Medic, a leader in the Japanese ophthalmic sector, as our exclusive distributor for AdenoPlus in this market, which is the second largest of the world.

"AdenoPlus is an in-vitro diagnostic medical device that aids in the differential diagnosis of acute conjunctivitis."

"We believe that the high-accuracy of AdenoPlus and its easy-to-use characteristics, together with the relationships of Nitto Medic amongst Japanese ophthalmologists, will contribute to the success of this innovative diagnostic tool."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the deal, Nitto will become the exclusive distributor of AdenoPlus in Japan as well as pay a €500,000 upfront payment and also buy these devices from Nicox.

Nitto Medic will be responsible for securing the relevant regulatory approval in Japan before launch of AdenoPlus, which is expected to take place within the next 18 months.

Nitto Medic president and chief executive officer Ryu Nakai said: "We are very excited about this agreement with Nicox.

"We are confident that AdenoPlus will greatly contribute to the healthcare and welfare of people in Japan.

We do hope that this first agreement with Nicox will be the beginning of a long-lasting collaboration as well as on future product opportunities."

In the first half of 2014, Nicox launched AdenoPlus in the five main European markets including France, Germany, Italy, Spain and the UK.

The company has also established partnerships with third parties in other territories, including Switzerland, Turkey, Benelux, South Africa and Poland.